Cargando…

Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant

Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yi, Back, Catherine R., Gräwert, Melissa A., Wahid, Ayla A., Denton, Harriet, Kildani, Rebecca, Paulin, Joshua, Wörner, Kristin, Kaiser, Wolgang, Svergun, Dmitri I., Sartbaeva, Asel, Watts, Andrew G., Marchbank, Kevin J., van den Elsen, Jean M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336717/
https://www.ncbi.nlm.nih.gov/pubmed/30687332
http://dx.doi.org/10.3389/fimmu.2018.03139
_version_ 1783388101118263296
author Yang, Yi
Back, Catherine R.
Gräwert, Melissa A.
Wahid, Ayla A.
Denton, Harriet
Kildani, Rebecca
Paulin, Joshua
Wörner, Kristin
Kaiser, Wolgang
Svergun, Dmitri I.
Sartbaeva, Asel
Watts, Andrew G.
Marchbank, Kevin J.
van den Elsen, Jean M. H.
author_facet Yang, Yi
Back, Catherine R.
Gräwert, Melissa A.
Wahid, Ayla A.
Denton, Harriet
Kildani, Rebecca
Paulin, Joshua
Wörner, Kristin
Kaiser, Wolgang
Svergun, Dmitri I.
Sartbaeva, Asel
Watts, Andrew G.
Marchbank, Kevin J.
van den Elsen, Jean M. H.
author_sort Yang, Yi
collection PubMed
description Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these linear arrays of C3d multimers do not mimic the natural opsonisation of antigens with C3d. Here we investigate the potential of using the unique complement activating characteristics of Staphylococcal immune-evasion protein Sbi to develop a pro-vaccine approach that spontaneously coats antigens with C3 degradation products in a natural way. We show that Sbi rapidly triggers the alternative complement pathway through recruitment of complement regulators, forming tripartite complexes that act as competitive antagonists of factor H, resulting in enhanced complement consumption. These functional results are corroborated by the structure of the complement activating Sbi-III-IV:C3d:FHR-1 complex. Finally, we demonstrate that Sbi, fused with Mycobacterium tuberculosis antigen Ag85b, causes efficient opsonisation with C3 fragments, thereby enhancing the immune response significantly beyond that of Ag85b alone, providing proof of concept for our pro-vaccine approach.
format Online
Article
Text
id pubmed-6336717
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63367172019-01-25 Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant Yang, Yi Back, Catherine R. Gräwert, Melissa A. Wahid, Ayla A. Denton, Harriet Kildani, Rebecca Paulin, Joshua Wörner, Kristin Kaiser, Wolgang Svergun, Dmitri I. Sartbaeva, Asel Watts, Andrew G. Marchbank, Kevin J. van den Elsen, Jean M. H. Front Immunol Immunology Co-ligation of the B cell antigen receptor with complement receptor 2 on B-cells via a C3d-opsonised antigen complex significantly lowers the threshold required for B cell activation. Consequently, fusions of antigens with C3d polymers have shown great potential in vaccine design. However, these linear arrays of C3d multimers do not mimic the natural opsonisation of antigens with C3d. Here we investigate the potential of using the unique complement activating characteristics of Staphylococcal immune-evasion protein Sbi to develop a pro-vaccine approach that spontaneously coats antigens with C3 degradation products in a natural way. We show that Sbi rapidly triggers the alternative complement pathway through recruitment of complement regulators, forming tripartite complexes that act as competitive antagonists of factor H, resulting in enhanced complement consumption. These functional results are corroborated by the structure of the complement activating Sbi-III-IV:C3d:FHR-1 complex. Finally, we demonstrate that Sbi, fused with Mycobacterium tuberculosis antigen Ag85b, causes efficient opsonisation with C3 fragments, thereby enhancing the immune response significantly beyond that of Ag85b alone, providing proof of concept for our pro-vaccine approach. Frontiers Media S.A. 2019-01-11 /pmc/articles/PMC6336717/ /pubmed/30687332 http://dx.doi.org/10.3389/fimmu.2018.03139 Text en Copyright © 2019 Yang, Back, Gräwert, Wahid, Denton, Kildani, Paulin, Wörner, Kaiser, Svergun, Sartbaeva, Watts, Marchbank and van den Elsen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yang, Yi
Back, Catherine R.
Gräwert, Melissa A.
Wahid, Ayla A.
Denton, Harriet
Kildani, Rebecca
Paulin, Joshua
Wörner, Kristin
Kaiser, Wolgang
Svergun, Dmitri I.
Sartbaeva, Asel
Watts, Andrew G.
Marchbank, Kevin J.
van den Elsen, Jean M. H.
Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title_full Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title_fullStr Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title_full_unstemmed Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title_short Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant
title_sort utilization of staphylococcal immune evasion protein sbi as a novel vaccine adjuvant
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336717/
https://www.ncbi.nlm.nih.gov/pubmed/30687332
http://dx.doi.org/10.3389/fimmu.2018.03139
work_keys_str_mv AT yangyi utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT backcatheriner utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT grawertmelissaa utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT wahidaylaa utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT dentonharriet utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT kildanirebecca utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT paulinjoshua utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT wornerkristin utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT kaiserwolgang utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT svergundmitrii utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT sartbaevaasel utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT wattsandrewg utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT marchbankkevinj utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant
AT vandenelsenjeanmh utilizationofstaphylococcalimmuneevasionproteinsbiasanovelvaccineadjuvant